Q-omics provides the consensus-scored TTC4P1 profile across patient tissues and cancer cell-line models. TTC4P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TTC4P1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, TTC4P1 RNA expression shows 14,690 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, KIRC, and PDAC as cancer lineages where TTC4P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC4P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC4P1 survival associations across molecular data types. TTC4P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC4P1 RNA expression–survival associations across cancer types. High TTC4P1 expression shows unfavorable associations in SARC, BLCA and HNSC, but favorable associations in SKCM, ESCA and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TTC4P1 RNA expression.
This table summarizes TTC4P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TTC4P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC4P1 shows lower tumor expression in KICH, THCA, UCEC and BRCA and higher tumor expression in KIRC and LUAD. The KIRC box plot shows higher TTC4P1 RNA expression in tumor versus normal tissue (log2 FC = +0.607, t-test p < 0.001).
This table shows molecular features associated with TTC4P1 in patient tissues and cancer cell lines. In patient samples, TTC4P1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
